Rafael Holdings, Inc. (RFL)

US — Real Estate Sector
Peers: XHG  BEKE  CBRE  OPAD  SRRK  EVLO  VRCA  REPL 

Automate Your Wheel Strategy on RFL

With Tiblio's Option Bot, you can configure your own wheel strategy including RFL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RFL
  • Rev/Share 0.029
  • Book/Share 3.3487
  • PB 0.6609
  • Debt/Equity 0.0086
  • CurrentRatio 3.848
  • ROIC -0.2261

 

  • MktCap 72379752.0
  • FreeCF/Share -0.4541
  • PFCF -6.3148
  • PE -2.3261
  • Debt/Assets 0.0064
  • DivYield 0
  • ROE -0.2996

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 5

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
RFL
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025

Read More
image for news Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
CYTH, RFL
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company's shareholders. If you would like to discuss your legal rights regarding th.

Read More
image for news CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

About Rafael Holdings, Inc. (RFL)

  • IPO Date 2018-03-27
  • Website https://www.rafaelholdings.com
  • Industry Real Estate - Services
  • CEO Howard S. Jonas
  • Employees 28

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.